Stockscreener 앱 받기
43.96
3.26%
-1.48
Exelixis Inc 주식(EXEL)의 최신 뉴스
Exelixis, Inc. $EXEL Shares Sold by Nisa Investment Advisors LLC - MarketBeat
Exelixis, Inc. $EXEL Shares Sold by EULAV Asset Management - MarketBeat
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term - sharewise.com
Truist Financial Sticks to Their Buy Rating for Exelixis (EXEL) - The Globe and Mail
Exelixis, Inc. (EXEL): A Bull Case Theory - Finviz
Growth Recap: Is Exelixis Inc a play on infrastructure spendingM&A Rumor & Weekly High Momentum Picks - baoquankhu1.vn
EXELIXIS INC (NASDAQ:EXEL) Presents a High-Growth Momentum and Technical Breakout Opportunity - Chartmill
Meritage Portfolio Management Has $12.20 Million Stock Position in Exelixis, Inc. $EXEL - MarketBeat
InSilico Lands Drug Discovery Deal After Hong Kong IPO - Benzinga
Does Exelixis’ 2026 Revenue Guidance and Zanzalintinib Push Change The Bull Case For EXEL? - Sahm
Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report? - Finviz
Truist Securities raises Exelixis stock price target to $51 on oncology growth - Investing.com Canada
Truist Securities Adjusts Price Target on Exelixis to $51 From $49, Maintains Buy Rating - marketscreener.com
Exelixis, Inc. $EXEL Shares Sold by New York State Teachers Retirement System - MarketBeat
Citizens reiterates Market Outperform rating on Exelixis stock By Investing.com - Investing.com Canada
Analysts Offer Insights on Healthcare Companies: Inogen (INGN), Exelixis (EXEL) and Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
Exelixis Posts Preliminary '25 Results, Issues '26 Outlook - sharewise.com
EXEL: Franchise-focused oncology growth, strong 2025 results, and robust 2026 outlook driven by innovation - TradingView — Track All Markets
EXEL: Disciplined franchise strategy and strong pipeline drive growth in oncology markets - TradingView — Track All Markets
Exelixis cut to underperform at BofA on valuation and lack of catalysts - MSN
Lobbying Update: $30,000 of EXELIXIS INC. lobbying was just disclosed - Quiver Quantitative
Exelixis (NASDAQ:EXEL) Shares Gap DownShould You Sell? - MarketBeat
Exelixis Announces Preliminary Fiscal Year 2025 Financial Results and 2026 Guidance - TradingView — Track All Markets
Exelixis, Citigroup And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Exelixis, Inc. (EXEL) Stock Analysis: Exploring The 3.32% Potential Upside - DirectorsTalk Interviews
Exelixis (EXEL) Sets Ambitious Plans in Oncology Sector - GuruFocus
Exelixis says fiscal year 2026 net product revenues guidance of $2.325 billion$2.425 billion - marketscreener.com
Exelixis Says Fiscal Year 2026 Net Product Revenues Guidance Of $2.325 Billion$2.425 Billion - TradingView — Track All Markets
Daily News - FinancialContent
Technical Reactions to EXEL Trends in Macro Strategies - Stock Traders Daily
Exelixis Provides 2026 Financial Guidance: Anticipates $2.525B to $2.625B in Revenue - Intellectia AI
EXELIXIS Q4 2025 Earnings Preview: Recent $EXEL Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
CapEx per share of Exelixis, Inc. – FWB:EX9 - TradingView — Track All Markets
Exelixis jumps on phase 3 data for zanzalintinib in colorectal cancer - MSN
Moran Wealth Management LLC Sells 23,495 Shares of Exelixis, Inc. $EXEL - MarketBeat
Here's Why Exelixis (EXEL) is a Strong Value Stock - Yahoo Finance
How Natera ctDNA Partnership Around STELLAR-316 At Exelixis (EXEL) Has Changed Its Investment Story - Yahoo Finance
Assessing Exelixis (EXEL) Valuation After Zanzalintinib Phase 3 Success And STELLAR-316 Trial Plans - Yahoo Finance
Exelixis, Inc.Common Stock (NQ: EXEL - FinancialContent
EXELExelixis Announces Third Quarter 2009 Financial Results - ADVFN
EXEL: HC Wainwright Raises Price Target and Maintains Buy Rating - GuruFocus
How risky is Exelixis Inc. stock nowRate Cut & Smart Swing Trading Techniques - ulpravda.ru
EXEL Collaborates With Natera for Late-Stage Colorectal Cancer Study - Finviz
EXEL Receives Downgrade from Morgan Stanley, Price Target Increa - GuruFocus
What is the fair value of Exelixis Inc. stock nowMarket Trend Report & Risk Controlled Daily Plans - ulpravda.ru
Morgan Stanley Reiterates "Equal Weight" Rating for Exelixis (NASDAQ:EXEL) - MarketBeat
Is It Time To Reassess Exelixis (EXEL) After Strong Multi‑Year Share Price Gains - Yahoo Finance
What 10 Analyst Ratings Have To Say About Exelixis - Benzinga
Morgan Stanley Downgrades Exelixis to Equalweight, Price Target is $48 - marketscreener.com
EXEL FinancialsIncome Statement - Quiver Quantitative
2 Healthcare Stocks to Buy for 2026 and Beyond - Finviz
Free Technical Research Reports on Biotech Stocks -- Epizyme, Esperion Therapeutics, Exelixis, and Grifols - ADVFN
Robeco Institutional Asset Management B.V. Has $40.48 Million Stake in Exelixis, Inc. $EXEL - MarketBeat
Exelixis stock rating downgraded by Morgan Stanley despite price target hike - Investing.com Canada
Exelixis and Natera to collaborate on MRD-guided cancer trial By Investing.com - Investing.com Nigeria
The Truth About Exelixis Inc: Is This Quiet Cancer Stock About To Explode? - AD HOC NEWS
Exelixis and Natera stocks rise on colorectal cancer trial collaboration By Investing.com - Investing.com Nigeria
Exelixis and Natera stocks rise on colorectal cancer trial collaboration - Investing.com
Exelixis, Natera to Collaborate on Phase 3 Colorectal Cancer Trial - marketscreener.com
Exelixis and Natera to collaborate on Stellar-316, a phase 3 pivotal trial of zanzalintinib - marketscreener.com
4.73%
0.92%
자본화:
|
볼륨(24시간):